<DOC>
	<DOCNO>NCT02603120</DOCNO>
	<brief_summary>This study evaluate efficacy switch regimen dolutegravir ( DTG ) abacavir/lamivudine ( ABC/3TC ) fix dose combination ( FDC ) abacavir/dolutegravir/lamivudine ( ABC/DTG/3TC ) FDC bictegravir/emtricitabine/tenofovir alafenamide ( B/F/TAF ) versus continue DTG ABC/3TC FDC ABC/DTG/3TC virologically suppress HIV-1 infected adult .</brief_summary>
	<brief_title>Safety Efficacy Switching From Dolutegravir ABC/3TC ABC/DTG/3TC B/F/TAF HIV-1 Infected Adults Who Are Virologically Suppressed</brief_title>
	<detailed_description />
	<mesh_term>Dolutegravir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Key Estimated glomerular filtration rate ≥ 50 mL/min ( ≥ 0.83 mL/sec ) Currently receive antiretroviral regimen DTG + ABC/3TC , ABC/DTG/3TC FDC ≥ 3 month prior screen visit HIV RNA &lt; 50 copies/mL screen visit Currently stable regimen ≥ 3 month precede screen visit document plasma HIV1 RNA &lt; 50 copies/mL ≥ 3 month precede screen visit ( undetectable HIV1 RNA level accord local assay use limit detection ≥ 50 copies/mL ) . Have document suspect resistance emtricitabine ( FTC ) , tenofovir ( TFV ) , DTG , ABC 3TC Key Current alcohol substance use judge Investigator potentially interfere subject study compliance Active tuberculosis infection Individuals experience decompensated cirrhosis ( eg , ascites , encephalopathy , variceal bleeding ) Females pregnant Females breastfeed Acute hepatitis 30 day prior study entry Chronic Hepatitis B Virus ( HBV ) infection Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>